Goldman Sachs BDC, Inc. Schedules Earnings Release and Conference Call to Announce Third Quarter 2015 Results

NEW YORK--(BUSINESS WIRE)-- Goldman Sachs BDC, Inc. (“GS BDC”) (NYSE: GSBD) announced today that it will report its third quarter ended September 30, 2015 financial results after the market closes on Thursday, November 5, 2015. GS BDC will also host an earnings conference call on Friday, November 6, 2015 at 10:00 am Eastern Time to discuss its quarterly financial results.

All interested parties are invited to participate via telephone or the audio webcast, which will be hosted on the Investor Resources section of GS BDC’s website at www.goldmansachsbdc.com.

Conference Call Information:

Domestic: (866) 884-8289

International: +1 (631) 485-4531

Conference ID: 56396832

All participants are asked to dial in approximately 10-15 minutes prior to the call, and reference “Goldman Sachs BDC, Inc.” when prompted.

Replay Information:

An archived replay of the call will be available from approximately 1:00 pm Eastern Time on November 6 through December 5. To hear the replay, please find dial-in numbers listed below. An archived replay will also be available on our webcast link located on the Investor Resources section of our website.

Domestic: (855) 859-2056

International: +1 (404) 537-3406

Conference ID: 56396832

Please direct any questions regarding obtaining access to the conference call to Goldman Sachs BDC, Inc. Investor Relations, via e-mail, at [email protected].

ABOUT GOLDMAN SACHS BDC, INC.

Goldman Sachs BDC, Inc. is a specialty finance company that has elected to be regulated as a business development company under the Investment Company Act of 1940. GS BDC was formed by The Goldman Sachs Group, Inc. (“Goldman Sachs”) to invest primarily in middle-market companies in the United States, and is externally managed by Goldman Sachs Asset Management, L.P., an SEC-registered investment adviser and a wholly-owned subsidiary of Goldman Sachs. GS BDC seeks to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including first lien, first lien/last-out unitranche and second lien debt, and unsecured debt, including mezzanine debt, as well as through select equity investments. For more information, visit www.goldmansachsbdc.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151006006820/en/

Goldman Sachs BDC, Inc.
Investor:
Katherine Schneider, 203-983-2529
or
Media:
Andrew Williams, 212-902-5400

Source: Goldman Sachs BDC, Inc.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Trump Media & Technology Group (DJT) Provides Additional Information to DJT Investors on Short Selling
• Phio Pharmaceuticals Corp. (PHIO) Reports Intratumoral Injection of PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells